Dataset Viewer
Auto-converted to Parquet
drug1_db
stringlengths
7
7
drug2_db
stringlengths
7
7
drug1_id
int64
0
1.69k
drug2_id
int64
0
1.69k
drug_pair
sequencelengths
2
2
drug1_name
stringlengths
4
85
drug2_name
stringlengths
4
85
drug1_desc
stringlengths
27
1.09k
drug2_desc
stringlengths
27
6.14k
label
stringclasses
3 values
label_idx
int64
0
2
all_paths
sequencelengths
1
10
all_paths_str
sequencelengths
1
10
path_str
stringlengths
0
3.57k
DB00448
DB01259
1,215
392
[ "DDInter1022", "DDInter1024" ]
Lansoprazole
Lapatinib
Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion.
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Moderate
1
[ [ [ 1215, 24, 392 ] ], [ [ 1215, 6, 4973 ], [ 4973, 45, 392 ] ], [ [ 1215, 18, 4602 ], [ 4602, 57, 392 ] ], [ [ 1215, 21, 28674 ], [ 28674, 60, 392 ] ], [ [ 1215, 25, 1406 ], [ 1406, 63, 392 ] ], [ [ 1215, 24, 723 ], [ 723, 24, 392 ] ], [ [ 1215, 23, 263 ], [ 263, 63, 392 ] ], [ [ 1215, 63, 529 ], [ 529, 24, 392 ] ], [ [ 1215, 24, 875 ], [ 875, 63, 392 ] ], [ [ 1215, 25, 1195 ], [ 1195, 24, 392 ] ] ]
[ [ [ "Lansoprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lapatinib" ] ], [ [ "Lansoprazole", "{u} (Compound) binds {v} (Gene)", "ABCB1" ], [ "ABCB1", "{u} (Gene) is bound by {v} (Compound)", "Lapatinib" ] ], [ [ "Lansoprazole", "{u} (Compound) downregulates {v} (Gene)", "SUPV3L1" ], [ "SUPV3L1", "{u} (Gene) is downregulated by {v} (Compound)", "Lapatinib" ] ], [ [ "Lansoprazole", "{u} (Compound) causes {v} (Side Effect)", "Nail disorder" ], [ "Nail disorder", "{u} (Side Effect) is caused by {v} (Compound)", "Lapatinib" ] ], [ [ "Lansoprazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Neratinib" ], [ "Neratinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lapatinib" ] ], [ [ "Lansoprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aprepitant" ], [ "Aprepitant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lapatinib" ] ], [ [ "Lansoprazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Axitinib" ], [ "Axitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lapatinib" ] ], [ [ "Lansoprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluvoxamine" ], [ "Fluvoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lapatinib" ] ], [ [ "Lansoprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fosaprepitant" ], [ "Fosaprepitant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lapatinib" ] ], [ [ "Lansoprazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Erlotinib" ], [ "Erlotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lapatinib" ] ] ]
Lansoprazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound) Lansoprazole (Compound) downregulates SUPV3L1 (Gene) and SUPV3L1 (Gene) is downregulated by Lapatinib (Compound) Lansoprazole (Compound) causes Nail disorder (Side Effect) and Nail disorder (Side Effect) is caused by Lapatinib (Compound) Lansoprazole may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib and Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib Lansoprazole may lead to a major life threatening interaction when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
DB00366
DB00408
1,594
1,408
[ "DDInter600", "DDInter1099" ]
Doxylamine
Loxapine
Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism.
An antipsychotic agent used in schizophrenia. [PubChem]
Moderate
1
[ [ [ 1594, 24, 1408 ] ], [ [ 1594, 63, 902 ], [ 902, 40, 1408 ] ], [ [ 1594, 24, 1119 ], [ 1119, 1, 1408 ] ], [ [ 1594, 24, 523 ], [ 523, 40, 1408 ] ], [ [ 1594, 63, 1174 ], [ 1174, 1, 1408 ] ], [ [ 1594, 6, 10104 ], [ 10104, 45, 1408 ] ], [ [ 1594, 21, 29093 ], [ 29093, 60, 1408 ] ], [ [ 1594, 24, 262 ], [ 262, 63, 1408 ] ], [ [ 1594, 63, 1242 ], [ 1242, 24, 1408 ] ], [ [ 1594, 74, 701 ], [ 701, 24, 1408 ] ] ]
[ [ [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Loxapine" ] ], [ [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clobazam" ], [ "Clobazam", "{u} (Compound) resembles {v} (Compound)", "Loxapine" ] ], [ [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chlordiazepoxide" ], [ "Chlordiazepoxide", "{u} (Compound) resembles {v} (Compound)", "Loxapine" ] ], [ [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alprazolam" ], [ "Alprazolam", "{u} (Compound) resembles {v} (Compound)", "Loxapine" ] ], [ [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Temazepam" ], [ "Temazepam", "{u} (Compound) resembles {v} (Compound)", "Loxapine" ] ], [ [ "Doxylamine", "{u} (Compound) binds {v} (Gene)", "HRH1" ], [ "HRH1", "{u} (Gene) is bound by {v} (Compound)", "Loxapine" ] ], [ [ "Doxylamine", "{u} (Compound) causes {v} (Side Effect)", "Fatigue" ], [ "Fatigue", "{u} (Side Effect) is caused by {v} (Compound)", "Loxapine" ] ], [ [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clidinium" ], [ "Clidinium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Loxapine" ] ], [ [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cetirizine" ], [ "Cetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Loxapine" ] ], [ [ "Doxylamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Loxapine" ] ] ]
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Loxapine (Compound) Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlordiazepoxide and Chlordiazepoxide (Compound) resembles Loxapine (Compound) Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam (Compound) resembles Loxapine (Compound) Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Temazepam and Temazepam (Compound) resembles Loxapine (Compound) Doxylamine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Loxapine (Compound) Doxylamine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Loxapine (Compound) Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Loxapine Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Loxapine Doxylamine (Compound) resembles Clemastine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Loxapine
DB00598
DB00938
1,523
455
[ "DDInter1013", "DDInter1635" ]
Labetalol
Salmeterol
Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994.
Major
2
[ [ [ 1523, 25, 455 ] ], [ [ 1523, 25, 688 ], [ 688, 63, 455 ] ], [ [ 1523, 40, 371 ], [ 371, 63, 455 ] ], [ [ 1523, 40, 1188 ], [ 1188, 1, 455 ] ], [ [ 1523, 6, 3576 ], [ 3576, 45, 455 ] ], [ [ 1523, 21, 29024 ], [ 29024, 60, 455 ] ], [ [ 1523, 24, 167 ], [ 167, 23, 455 ] ], [ [ 1523, 63, 251 ], [ 251, 23, 455 ] ], [ [ 1523, 24, 708 ], [ 708, 62, 455 ] ], [ [ 1523, 24, 1593 ], [ 1593, 63, 455 ] ] ]
[ [ [ "Labetalol", "{u} may lead to a major life threatening interaction when taken with {v}", "Salmeterol" ] ], [ [ "Labetalol", "{u} may lead to a major life threatening interaction when taken with {v}", "Salbutamol" ], [ "Salbutamol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Salmeterol" ] ], [ [ "Labetalol", "{u} (Compound) resembles {v} (Compound)", "Propafenone" ], [ "Propafenone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Salmeterol" ] ], [ [ "Labetalol", "{u} (Compound) resembles {v} (Compound)", "Arbutamine" ], [ "Arbutamine", "{u} (Compound) resembles {v} (Compound)", "Salmeterol" ] ], [ [ "Labetalol", "{u} (Compound) binds {v} (Gene)", "ADRB2" ], [ "ADRB2", "{u} (Gene) is bound by {v} (Compound)", "Salmeterol" ] ], [ [ "Labetalol", "{u} (Compound) causes {v} (Side Effect)", "Hypertension" ], [ "Hypertension", "{u} (Side Effect) is caused by {v} (Compound)", "Salmeterol" ] ], [ [ "Labetalol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydrocortisone" ], [ "Hydrocortisone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Salmeterol" ] ], [ [ "Labetalol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Betamethasone" ], [ "Betamethasone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Salmeterol" ] ], [ [ "Labetalol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Corticotropin" ], [ "Corticotropin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Salmeterol" ] ], [ [ "Labetalol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Crizotinib" ], [ "Crizotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Salmeterol" ] ] ]
Labetalol may lead to a major life threatening interaction when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol Labetalol (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol Labetalol (Compound) resembles Arbutamine (Compound) and Arbutamine (Compound) resembles Salmeterol (Compound) Labetalol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Salmeterol (Compound) Labetalol (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Salmeterol (Compound) Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Salmeterol Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a minor interaction that can limit clinical effects when taken with Salmeterol Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a minor interaction that can limit clinical effects when taken with Salmeterol Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
DB00734
DB11986
1,664
484
[ "DDInter1605", "DDInter648" ]
Risperidone
Entrectinib
Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone). Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's
Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.
Moderate
1
[ [ [ 1664, 24, 484 ] ], [ [ 1664, 23, 112 ], [ 112, 23, 484 ] ], [ [ 1664, 24, 222 ], [ 222, 23, 484 ] ], [ [ 1664, 24, 774 ], [ 774, 24, 484 ] ], [ [ 1664, 63, 322 ], [ 322, 24, 484 ] ], [ [ 1664, 24, 159 ], [ 159, 63, 484 ] ], [ [ 1664, 62, 752 ], [ 752, 24, 484 ] ], [ [ 1664, 1, 519 ], [ 519, 24, 484 ] ], [ [ 1664, 25, 985 ], [ 985, 25, 484 ] ], [ [ 1664, 25, 877 ], [ 877, 64, 484 ] ] ]
[ [ [ "Risperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Entrectinib" ] ], [ [ "Risperidone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Entrectinib" ] ], [ [ "Risperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Entrectinib" ] ], [ [ "Risperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Degarelix" ], [ "Degarelix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Entrectinib" ] ], [ [ "Risperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Epirubicin" ], [ "Epirubicin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Entrectinib" ] ], [ [ "Risperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ], [ "Larotrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Entrectinib" ] ], [ [ "Risperidone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Cimetidine" ], [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Entrectinib" ] ], [ [ "Risperidone", "{u} (Compound) resembles {v} (Compound)", "Paliperidone" ], [ "Paliperidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Entrectinib" ] ], [ [ "Risperidone", "{u} may lead to a major life threatening interaction when taken with {v}", "Osimertinib" ], [ "Osimertinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Entrectinib" ] ], [ [ "Risperidone", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ], [ "Macimorelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Entrectinib" ] ] ]
Risperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Entrectinib Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib Risperidone may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib Risperidone (Compound) resembles Paliperidone (Compound) and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib Risperidone may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Entrectinib Risperidone may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Entrectinib
DB09276
DB11989
381
1,434
[ "DDInter1682", "DDInter183" ]
Sodium aurothiomalate
Benznidazole
Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis.
Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease.
Moderate
1
[ [ [ 381, 24, 1434 ] ], [ [ 381, 63, 375 ], [ 375, 24, 1434 ] ], [ [ 381, 24, 148 ], [ 148, 63, 1434 ] ], [ [ 381, 24, 1480 ], [ 1480, 24, 1434 ] ], [ [ 381, 64, 1487 ], [ 1487, 24, 1434 ] ], [ [ 381, 63, 375 ], [ 375, 63, 788 ], [ 788, 24, 1434 ] ], [ [ 381, 63, 309 ], [ 309, 24, 788 ], [ 788, 24, 1434 ] ], [ [ 381, 24, 148 ], [ 148, 63, 788 ], [ 788, 24, 1434 ] ], [ [ 381, 64, 1487 ], [ 1487, 24, 788 ], [ 788, 24, 1434 ] ], [ [ 381, 64, 1377 ], [ 1377, 25, 788 ], [ 788, 24, 1434 ] ] ]
[ [ [ "Sodium aurothiomalate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Benznidazole" ] ], [ [ "Sodium aurothiomalate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Certolizumab pegol" ], [ "Certolizumab pegol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Benznidazole" ] ], [ [ "Sodium aurothiomalate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Secnidazole" ], [ "Secnidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Benznidazole" ] ], [ [ "Sodium aurothiomalate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixazomib" ], [ "Ixazomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Benznidazole" ] ], [ [ "Sodium aurothiomalate", "{u} may lead to a major life threatening interaction when taken with {v}", "Hydroxychloroquine" ], [ "Hydroxychloroquine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Benznidazole" ] ], [ [ "Sodium aurothiomalate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Certolizumab pegol" ], [ "Certolizumab pegol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pitavastatin" ], [ "Pitavastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Benznidazole" ] ], [ [ "Sodium aurothiomalate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixabepilone" ], [ "Ixabepilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pitavastatin" ], [ "Pitavastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Benznidazole" ] ], [ [ "Sodium aurothiomalate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Secnidazole" ], [ "Secnidazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pitavastatin" ], [ "Pitavastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Benznidazole" ] ], [ [ "Sodium aurothiomalate", "{u} may lead to a major life threatening interaction when taken with {v}", "Hydroxychloroquine" ], [ "Hydroxychloroquine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pitavastatin" ], [ "Pitavastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Benznidazole" ] ], [ [ "Sodium aurothiomalate", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Pitavastatin" ], [ "Pitavastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Benznidazole" ] ] ]
Sodium aurothiomalate may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole Sodium aurothiomalate may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole Sodium aurothiomalate may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole Sodium aurothiomalate may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole Sodium aurothiomalate may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole Sodium aurothiomalate may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole Sodium aurothiomalate may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole Sodium aurothiomalate may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole Sodium aurothiomalate may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
DB08882
DB12141
1,281
971
[ "DDInter1070", "DDInter817" ]
Linagliptin
Gilteritinib
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
Moderate
1
[ [ [ 1281, 24, 971 ] ], [ [ 1281, 63, 485 ], [ 485, 24, 971 ] ], [ [ 1281, 24, 1097 ], [ 1097, 24, 971 ] ], [ [ 1281, 24, 1598 ], [ 1598, 63, 971 ] ], [ [ 1281, 64, 1101 ], [ 1101, 25, 971 ] ], [ [ 1281, 63, 1327 ], [ 1327, 25, 971 ] ], [ [ 1281, 24, 982 ], [ 982, 64, 971 ] ], [ [ 1281, 24, 913 ], [ 913, 25, 971 ] ], [ [ 1281, 63, 485 ], [ 485, 23, 1247 ], [ 1247, 23, 971 ] ], [ [ 1281, 24, 1097 ], [ 1097, 63, 1135 ], [ 1135, 23, 971 ] ] ]
[ [ [ "Linagliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ] ], [ [ "Linagliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentamidine" ], [ "Pentamidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ] ], [ [ "Linagliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lasmiditan" ], [ "Lasmiditan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ] ], [ [ "Linagliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tazemetostat" ], [ "Tazemetostat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ] ], [ [ "Linagliptin", "{u} may lead to a major life threatening interaction when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may lead to a major life threatening interaction when taken with {v}", "Gilteritinib" ] ], [ [ "Linagliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Saquinavir" ], [ "Saquinavir", "{u} may lead to a major life threatening interaction when taken with {v}", "Gilteritinib" ] ], [ [ "Linagliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ], [ "Ivosidenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Gilteritinib" ] ], [ [ "Linagliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Apalutamide" ], [ "Apalutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Gilteritinib" ] ], [ [ "Linagliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentamidine" ], [ "Pentamidine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sulfamethoxazole" ], [ "Sulfamethoxazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Gilteritinib" ] ], [ [ "Linagliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lasmiditan" ], [ "Lasmiditan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Gilteritinib" ] ] ]
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and Lasmiditan may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib Linagliptin may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Gilteritinib Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir may lead to a major life threatening interaction when taken with Gilteritinib Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Gilteritinib Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Gilteritinib Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and Lasmiditan may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
DB00802
DB01233
1,322
1,311
[ "DDInter43", "DDInter1197" ]
Alfentanil
Metoclopramide
A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.
Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures. One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route. Metoclopramide was initially approved by the FDA in 1980.
Moderate
1
[ [ [ 1322, 24, 1311 ] ], [ [ 1322, 21, 28691 ], [ 28691, 60, 1311 ] ], [ [ 1322, 24, 1383 ], [ 1383, 63, 1311 ] ], [ [ 1322, 24, 629 ], [ 629, 24, 1311 ] ], [ [ 1322, 63, 662 ], [ 662, 24, 1311 ] ], [ [ 1322, 25, 1053 ], [ 1053, 24, 1311 ] ], [ [ 1322, 40, 704 ], [ 704, 24, 1311 ] ], [ [ 1322, 64, 121 ], [ 121, 24, 1311 ] ], [ [ 1322, 25, 760 ], [ 760, 63, 1311 ] ], [ [ 1322, 24, 104 ], [ 104, 25, 1311 ] ] ]
[ [ [ "Alfentanil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metoclopramide" ] ], [ [ "Alfentanil", "{u} (Compound) causes {v} (Side Effect)", "Somnolence" ], [ "Somnolence", "{u} (Side Effect) is caused by {v} (Compound)", "Metoclopramide" ] ], [ [ "Alfentanil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sodium sulfate" ], [ "Sodium sulfate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metoclopramide" ] ], [ [ "Alfentanil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sirolimus" ], [ "Sirolimus", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metoclopramide" ] ], [ [ "Alfentanil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbinoxamine" ], [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metoclopramide" ] ], [ [ "Alfentanil", "{u} may lead to a major life threatening interaction when taken with {v}", "Procarbazine" ], [ "Procarbazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metoclopramide" ] ], [ [ "Alfentanil", "{u} (Compound) resembles {v} (Compound)", "Fentanyl" ], [ "Fentanyl", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metoclopramide" ] ], [ [ "Alfentanil", "{u} may lead to a major life threatening interaction when taken with {v}", "Fenfluramine" ], [ "Fenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metoclopramide" ] ], [ [ "Alfentanil", "{u} may lead to a major life threatening interaction when taken with {v}", "Cobicistat" ], [ "Cobicistat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metoclopramide" ] ], [ [ "Alfentanil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methdilazine" ], [ "Methdilazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Metoclopramide" ] ] ]
Alfentanil (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound) Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide Alfentanil may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide Alfentanil (Compound) resembles Fentanyl (Compound) and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide Alfentanil may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide Alfentanil may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may lead to a major life threatening interaction when taken with Metoclopramide
DB00413
DB06282
1,346
516
[ "DDInter1505", "DDInter1053" ]
Pramipexole
Levocetirizine
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement). It was first approved by the FDA in 1997. Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients, leading to increased difficulty in performing activities of daily living due to symptoms that progress over time. The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016. This increase may be attributed to an aging population along with other contributing factors. In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (
Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995.
Moderate
1
[ [ [ 1346, 24, 516 ] ], [ [ 1346, 63, 701 ], [ 701, 24, 516 ] ], [ [ 1346, 24, 1614 ], [ 1614, 24, 516 ] ], [ [ 1346, 24, 407 ], [ 407, 63, 516 ] ], [ [ 1346, 63, 701 ], [ 701, 23, 771 ], [ 771, 62, 516 ] ], [ [ 1346, 24, 1614 ], [ 1614, 63, 701 ], [ 701, 24, 516 ] ], [ [ 1346, 63, 999 ], [ 999, 63, 701 ], [ 701, 24, 516 ] ], [ [ 1346, 24, 100 ], [ 100, 23, 771 ], [ 771, 62, 516 ] ], [ [ 1346, 63, 1594 ], [ 1594, 74, 701 ], [ 701, 24, 516 ] ], [ [ 1346, 21, 28666 ], [ 28666, 60, 1031 ], [ 1031, 23, 516 ] ] ]
[ [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ], [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Hyaluronidase" ], [ "Hyaluronidase", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Levocetirizine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ], [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Hyaluronidase" ], [ "Hyaluronidase", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Levocetirizine" ] ], [ [ "Pramipexole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ] ], [ [ "Pramipexole", "{u} (Compound) causes {v} (Side Effect)", "Nervous system disorder" ], [ "Nervous system disorder", "{u} (Side Effect) is caused by {v} (Compound)", "Theophylline" ], [ "Theophylline", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Levocetirizine" ] ] ]
Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Levocetirizine Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Levocetirizine Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Clemastine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine Pramipexole (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Theophylline (Compound) and Theophylline may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
DB00031
DB06081
20
1,046
[ "DDInter1764", "DDInter286" ]
Tenecteplase
Caplacizumab
Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.
Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.
Major
2
[ [ [ 20, 25, 1046 ] ], [ [ 20, 23, 1631 ], [ 1631, 62, 1046 ] ], [ [ 20, 24, 1039 ], [ 1039, 24, 1046 ] ], [ [ 20, 24, 1427 ], [ 1427, 63, 1046 ] ], [ [ 20, 24, 1479 ], [ 1479, 25, 1046 ] ], [ [ 20, 25, 256 ], [ 256, 64, 1046 ] ], [ [ 20, 25, 4 ], [ 4, 25, 1046 ] ], [ [ 20, 24, 578 ], [ 578, 64, 1046 ] ], [ [ 20, 64, 942 ], [ 942, 25, 1046 ] ], [ [ 20, 23, 1631 ], [ 1631, 62, 1479 ], [ 1479, 25, 1046 ] ] ]
[ [ [ "Tenecteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Caplacizumab" ] ], [ [ "Tenecteplase", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Turmeric" ], [ "Turmeric", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Caplacizumab" ] ], [ [ "Tenecteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ], [ "Dexfenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Caplacizumab" ] ], [ [ "Tenecteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vortioxetine" ], [ "Vortioxetine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Caplacizumab" ] ], [ [ "Tenecteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylsalicylic acid" ], [ "Acetylsalicylic acid", "{u} may lead to a major life threatening interaction when taken with {v}", "Caplacizumab" ] ], [ [ "Tenecteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Prasugrel" ], [ "Prasugrel", "{u} may lead to a major life threatening interaction when taken with {v}", "Caplacizumab" ] ], [ [ "Tenecteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ], [ "Omacetaxine mepesuccinate", "{u} may lead to a major life threatening interaction when taken with {v}", "Caplacizumab" ] ], [ [ "Tenecteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may lead to a major life threatening interaction when taken with {v}", "Caplacizumab" ] ], [ [ "Tenecteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Bivalirudin" ], [ "Bivalirudin", "{u} may lead to a major life threatening interaction when taken with {v}", "Caplacizumab" ] ], [ [ "Tenecteplase", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Turmeric" ], [ "Turmeric", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Acetylsalicylic acid" ], [ "Acetylsalicylic acid", "{u} may lead to a major life threatening interaction when taken with {v}", "Caplacizumab" ] ] ]
Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Caplacizumab Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Caplacizumab Tenecteplase may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may lead to a major life threatening interaction when taken with Caplacizumab Tenecteplase may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Caplacizumab Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Caplacizumab Tenecteplase may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may lead to a major life threatening interaction when taken with Caplacizumab Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Caplacizumab
DB06788
DB13139
1,616
1,032
[ "DDInter864", "DDInter1063" ]
Histrelin
Levosalbutamol
Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of
Levosalbutamol, or levalbuterol, is a short-acting Ξ²2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol).
Moderate
1
[ [ [ 1616, 24, 1032 ] ], [ [ 1616, 25, 1618 ], [ 1618, 24, 1032 ] ], [ [ 1616, 24, 124 ], [ 124, 24, 1032 ] ], [ [ 1616, 63, 594 ], [ 594, 24, 1032 ] ], [ [ 1616, 25, 982 ], [ 982, 63, 1032 ] ], [ [ 1616, 64, 1493 ], [ 1493, 24, 1032 ] ], [ [ 1616, 25, 877 ], [ 877, 25, 1032 ] ], [ [ 1616, 25, 1618 ], [ 1618, 63, 1220 ], [ 1220, 23, 1032 ] ], [ [ 1616, 24, 124 ], [ 124, 64, 1220 ], [ 1220, 23, 1032 ] ], [ [ 1616, 63, 594 ], [ 594, 64, 1220 ], [ 1220, 23, 1032 ] ] ]
[ [ [ "Histrelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levosalbutamol" ] ], [ [ "Histrelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Cabozantinib" ], [ "Cabozantinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levosalbutamol" ] ], [ [ "Histrelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ], [ "Glasdegib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levosalbutamol" ] ], [ [ "Histrelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bosutinib" ], [ "Bosutinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levosalbutamol" ] ], [ [ "Histrelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ], [ "Ivosidenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levosalbutamol" ] ], [ [ "Histrelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Halofantrine" ], [ "Halofantrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levosalbutamol" ] ], [ [ "Histrelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ], [ "Macimorelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Levosalbutamol" ] ], [ [ "Histrelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Cabozantinib" ], [ "Cabozantinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Levosalbutamol" ] ], [ [ "Histrelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ], [ "Glasdegib", "{u} may lead to a major life threatening interaction when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Levosalbutamol" ] ], [ [ "Histrelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bosutinib" ], [ "Bosutinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Levosalbutamol" ] ] ]
Histrelin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol Histrelin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol Histrelin may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol Histrelin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Levosalbutamol Histrelin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
DB00619
DB10429
1,419
200
[ "DDInter909", "DDInter282" ]
Imatinib
Candida albicans
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing.
Moderate
1
[ [ [ 1419, 24, 200 ] ], [ [ 1419, 24, 1683 ], [ 1683, 24, 200 ] ], [ [ 1419, 25, 976 ], [ 976, 24, 200 ] ], [ [ 1419, 25, 1019 ], [ 1019, 63, 200 ] ], [ [ 1419, 63, 147 ], [ 147, 24, 200 ] ], [ [ 1419, 24, 564 ], [ 564, 63, 200 ] ], [ [ 1419, 62, 1101 ], [ 1101, 24, 200 ] ], [ [ 1419, 35, 478 ], [ 478, 24, 200 ] ], [ [ 1419, 64, 1064 ], [ 1064, 24, 200 ] ], [ [ 1419, 24, 1683 ], [ 1683, 63, 1096 ], [ 1096, 24, 200 ] ] ]
[ [ [ "Imatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Imatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ], [ "Ustekinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Imatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Imatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Deflazacort" ], [ "Deflazacort", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Imatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vinblastine" ], [ "Vinblastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Imatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Abemaciclib" ], [ "Abemaciclib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Imatinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Imatinib", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nilotinib" ], [ "Nilotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Imatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Cladribine" ], [ "Cladribine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ], [ [ "Imatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ], [ "Ustekinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mycophenolic acid" ], [ "Mycophenolic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Candida albicans" ] ] ]
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Imatinib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Imatinib may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib and Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Imatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Imatinib (Compound) resembles Nilotinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Imatinib may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
DB00968
DB11921
1,551
1,019
[ "DDInter1185", "DDInter492" ]
Methyldopa
Deflazacort
Methyldopa, or Ξ±-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(Ξ±)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. Methyldopa exists in two isomers D-Ξ±-methyldopa and L-Ξ±-methyldopa, which is the active form. First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. Since
Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340]
Moderate
1
[ [ [ 1551, 24, 1019 ] ], [ [ 1551, 23, 959 ], [ 959, 24, 1019 ] ], [ [ 1551, 24, 1344 ], [ 1344, 24, 1019 ] ], [ [ 1551, 62, 245 ], [ 245, 24, 1019 ] ], [ [ 1551, 63, 1560 ], [ 1560, 24, 1019 ] ], [ [ 1551, 63, 1314 ], [ 1314, 25, 1019 ] ], [ [ 1551, 24, 1220 ], [ 1220, 25, 1019 ] ], [ [ 1551, 25, 1510 ], [ 1510, 25, 1019 ] ], [ [ 1551, 23, 959 ], [ 959, 63, 1072 ], [ 1072, 23, 1019 ] ], [ [ 1551, 24, 1344 ], [ 1344, 63, 1072 ], [ 1072, 23, 1019 ] ] ]
[ [ [ "Methyldopa", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deflazacort" ] ], [ [ "Methyldopa", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deflazacort" ] ], [ [ "Methyldopa", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canagliflozin" ], [ "Canagliflozin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deflazacort" ] ], [ [ "Methyldopa", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Glimepiride" ], [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deflazacort" ] ], [ [ "Methyldopa", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pegaspargase" ], [ "Pegaspargase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deflazacort" ] ], [ [ "Methyldopa", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Desmopressin" ], [ "Desmopressin", "{u} may lead to a major life threatening interaction when taken with {v}", "Deflazacort" ] ], [ [ "Methyldopa", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may lead to a major life threatening interaction when taken with {v}", "Deflazacort" ] ], [ [ "Methyldopa", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Deflazacort" ] ], [ [ "Methyldopa", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Isoniazid" ], [ "Isoniazid", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Deflazacort" ] ], [ [ "Methyldopa", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canagliflozin" ], [ "Canagliflozin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Isoniazid" ], [ "Isoniazid", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Deflazacort" ] ] ]
Methyldopa may cause a minor interaction that can limit clinical effects when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort Methyldopa may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin may lead to a major life threatening interaction when taken with Deflazacort Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Deflazacort Methyldopa may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Deflazacort Methyldopa may cause a minor interaction that can limit clinical effects when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
DB00270
DB01285
1,428
708
[ "DDInter993", "DDInter445" ]
Isradipine
Corticotropin
Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension.
Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
Moderate
1
[ [ [ 1428, 24, 708 ] ], [ [ 1428, 24, 1450 ], [ 1450, 63, 708 ] ], [ [ 1428, 63, 1184 ], [ 1184, 24, 708 ] ], [ [ 1428, 24, 544 ], [ 544, 24, 708 ] ], [ [ 1428, 1, 336 ], [ 336, 24, 708 ] ], [ [ 1428, 63, 1057 ], [ 1057, 25, 708 ] ], [ [ 1428, 24, 593 ], [ 593, 25, 708 ] ], [ [ 1428, 24, 375 ], [ 375, 64, 708 ] ], [ [ 1428, 24, 1450 ], [ 1450, 63, 455 ], [ 455, 23, 708 ] ], [ [ 1428, 63, 1184 ], [ 1184, 24, 126 ], [ 126, 24, 708 ] ] ]
[ [ [ "Isradipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Corticotropin" ] ], [ [ "Isradipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Empagliflozin" ], [ "Empagliflozin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Corticotropin" ] ], [ [ "Isradipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Anakinra" ], [ "Anakinra", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Corticotropin" ] ], [ [ "Isradipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium sulfate" ], [ "Magnesium sulfate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Corticotropin" ] ], [ [ "Isradipine", "{u} (Compound) resembles {v} (Compound)", "Nifedipine" ], [ "Nifedipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Corticotropin" ] ], [ [ "Isradipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Etanercept" ], [ "Etanercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Corticotropin" ] ], [ [ "Isradipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bupropion" ], [ "Bupropion", "{u} may lead to a major life threatening interaction when taken with {v}", "Corticotropin" ] ], [ [ "Isradipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Certolizumab pegol" ], [ "Certolizumab pegol", "{u} may lead to a major life threatening interaction when taken with {v}", "Corticotropin" ] ], [ [ "Isradipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Empagliflozin" ], [ "Empagliflozin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Salmeterol" ], [ "Salmeterol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Corticotropin" ] ], [ [ "Isradipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Anakinra" ], [ "Anakinra", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Corticotropin" ] ] ]
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin Isradipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Corticotropin Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Corticotropin Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Corticotropin Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
DB00682
DB13873
126
1,534
[ "DDInter1951", "DDInter719" ]
Warfarin
Fenofibric acid
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile, prodrug ,[fenofibrate], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed for improved solubility, gastrointestinal absorption, and bioavailability, and more convenient administration.[A32038,A193362]
Major
2
[ [ [ 126, 25, 1534 ] ], [ [ 126, 24, 780 ], [ 780, 24, 1534 ] ], [ [ 126, 63, 305 ], [ 305, 24, 1534 ] ], [ [ 126, 62, 663 ], [ 663, 24, 1534 ] ], [ [ 126, 24, 1377 ], [ 1377, 25, 1534 ] ], [ [ 126, 62, 467 ], [ 467, 25, 1534 ] ], [ [ 126, 24, 780 ], [ 780, 63, 267 ], [ 267, 24, 1534 ] ], [ [ 126, 63, 305 ], [ 305, 24, 267 ], [ 267, 24, 1534 ] ], [ [ 126, 24, 1144 ], [ 1144, 24, 959 ], [ 959, 24, 1534 ] ], [ [ 126, 62, 663 ], [ 663, 24, 267 ], [ 267, 24, 1534 ] ] ]
[ [ [ "Warfarin", "{u} may lead to a major life threatening interaction when taken with {v}", "Fenofibric acid" ] ], [ [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chenodeoxycholic acid" ], [ "Chenodeoxycholic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenofibric acid" ] ], [ [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Asparaginase Escherichia coli" ], [ "Asparaginase Escherichia coli", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenofibric acid" ] ], [ [ "Warfarin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenofibric acid" ] ], [ [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Fenofibric acid" ] ], [ [ "Warfarin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Simvastatin" ], [ "Simvastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Fenofibric acid" ] ], [ [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chenodeoxycholic acid" ], [ "Chenodeoxycholic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naltrexone" ], [ "Naltrexone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenofibric acid" ] ], [ [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Asparaginase Escherichia coli" ], [ "Asparaginase Escherichia coli", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naltrexone" ], [ "Naltrexone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenofibric acid" ] ], [ [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ], [ "Nateglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenofibric acid" ] ], [ [ "Warfarin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naltrexone" ], [ "Naltrexone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenofibric acid" ] ] ]
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Chenodeoxycholic acid and Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid Warfarin may cause a minor interaction that can limit clinical effects when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Fenofibric acid Warfarin may cause a minor interaction that can limit clinical effects when taken with Simvastatin and Simvastatin may lead to a major life threatening interaction when taken with Fenofibric acid Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Chenodeoxycholic acid and Chenodeoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid Warfarin may cause a minor interaction that can limit clinical effects when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
DB01110
DB06207
86
910
[ "DDInter1209", "DDInter1667" ]
Miconazole
Silodosin
Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14Ξ±-lanosterol demethylase activity.[A203636, A203639] Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream.[A214523, L14021] It is currently available as a variety of prescription and over the counter products. Despite having been in clinical use for an extended period, resistance to m
Silodosin is a selective antagonist of alpha(Ξ±)-1 adrenergic receptors that binds to the Ξ±<sub>1A</sub> subtype with the highest affinity. Ξ±1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the Ξ±<sub>1A</sub> subtype accounts for approximately 75% of Ξ±1-adrenoceptors in the prostate. Silodosin was first approved by the FDA in October 2008 and it is also approved in Europe and Canada. Silodosin is available as oral capsules with common trade names Rapaflo and Urorec. It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults. Most commonly affecting males over the age of 40 years, benign prostatic hyperplasia is the non-malignant enlargement of the prostate gland, associated with lower urinary tract symptoms that have a negative impact on the quality of life of patients. Silodosin works by binding to Ξ±<sub>1A</sub>-adrenoceptors with high affinity and relaxing the lower urinary tract, thereby improving urinary symptoms and alleviating bladder outlet obstruction.
Moderate
1
[ [ [ 86, 24, 910 ] ], [ [ 86, 6, 8374 ], [ 8374, 45, 910 ] ], [ [ 86, 21, 28779 ], [ 28779, 60, 910 ] ], [ [ 86, 24, 484 ], [ 484, 63, 910 ] ], [ [ 86, 24, 478 ], [ 478, 24, 910 ] ], [ [ 86, 63, 1424 ], [ 1424, 24, 910 ] ], [ [ 86, 25, 1670 ], [ 1670, 63, 910 ] ], [ [ 86, 62, 1101 ], [ 1101, 24, 910 ] ], [ [ 86, 24, 760 ], [ 760, 64, 910 ] ], [ [ 86, 6, 8374 ], [ 8374, 45, 1139 ], [ 1139, 1, 910 ] ] ]
[ [ [ "Miconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Silodosin" ] ], [ [ "Miconazole", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Silodosin" ] ], [ [ "Miconazole", "{u} (Compound) causes {v} (Side Effect)", "Dry mouth" ], [ "Dry mouth", "{u} (Side Effect) is caused by {v} (Compound)", "Silodosin" ] ], [ [ "Miconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Entrectinib" ], [ "Entrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Silodosin" ] ], [ [ "Miconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nilotinib" ], [ "Nilotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Silodosin" ] ], [ [ "Miconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quinine" ], [ "Quinine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Silodosin" ] ], [ [ "Miconazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Eliglustat" ], [ "Eliglustat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Silodosin" ] ], [ [ "Miconazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Silodosin" ] ], [ [ "Miconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cobicistat" ], [ "Cobicistat", "{u} may lead to a major life threatening interaction when taken with {v}", "Silodosin" ] ], [ [ "Miconazole", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Tamsulosin" ], [ "Tamsulosin", "{u} (Compound) resembles {v} (Compound)", "Silodosin" ] ] ]
Miconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Silodosin (Compound) Miconazole (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Silodosin (Compound) Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Silodosin Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Silodosin Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Silodosin Miconazole may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Silodosin Miconazole may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Silodosin Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Silodosin Miconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tamsulosin (Compound) and Tamsulosin (Compound) resembles Silodosin (Compound)
DB00554
DB00619
1,027
1,419
[ "DDInter1478", "DDInter909" ]
Piroxicam
Imatinib
A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Moderate
1
[ [ [ 1027, 24, 1419 ] ], [ [ 1027, 6, 6017 ], [ 6017, 45, 1419 ] ], [ [ 1027, 24, 222 ], [ 222, 62, 1419 ] ], [ [ 1027, 24, 1619 ], [ 1619, 63, 1419 ] ], [ [ 1027, 63, 305 ], [ 305, 24, 1419 ] ], [ [ 1027, 40, 1335 ], [ 1335, 63, 1419 ] ], [ [ 1027, 25, 1213 ], [ 1213, 63, 1419 ] ], [ [ 1027, 62, 752 ], [ 752, 24, 1419 ] ], [ [ 1027, 24, 121 ], [ 121, 24, 1419 ] ], [ [ 1027, 25, 663 ], [ 663, 24, 1419 ] ] ]
[ [ [ "Piroxicam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ] ], [ [ "Piroxicam", "{u} (Compound) binds {v} (Gene)", "CYP2C9" ], [ "CYP2C9", "{u} (Gene) is bound by {v} (Compound)", "Imatinib" ] ], [ [ "Piroxicam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Imatinib" ] ], [ [ "Piroxicam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ], [ "Rucaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ] ], [ [ "Piroxicam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Asparaginase Escherichia coli" ], [ "Asparaginase Escherichia coli", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ] ], [ [ "Piroxicam", "{u} (Compound) resembles {v} (Compound)", "Oxcarbazepine" ], [ "Oxcarbazepine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ] ], [ [ "Piroxicam", "{u} may lead to a major life threatening interaction when taken with {v}", "Dasatinib" ], [ "Dasatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ] ], [ [ "Piroxicam", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Cimetidine" ], [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ] ], [ [ "Piroxicam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fenfluramine" ], [ "Fenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ] ], [ [ "Piroxicam", "{u} may lead to a major life threatening interaction when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ] ] ]
Piroxicam (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Imatinib (Compound) Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Imatinib Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Imatinib Piroxicam (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib Piroxicam may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib Piroxicam may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib Piroxicam may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
DB01175
DB09564
318
1,296
[ "DDInter672", "DDInter930" ]
Escitalopram
Insulin degludec
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism.[A18561,A18562,A18563,A18564,A174934] Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle.[A18561,A18562,A18563,A18564,A174934] Absorption of glucose into cells allows for its transformation into glycogen or fat for storage.[A18561,A18562,A18563,A18564,A174934] Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.[A18561,A18562,A18563,A18564,A174934] Insulin is an essential treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels.[A18561,A18562,A18563,A18564,A174934] As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin degludec, to lower glucose levels in the blood.[A18561,A18562,A18563,A18564,A174934] Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels.[A18561,A18562,A18563,A18564,A174934] Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed later in the course of T2D, after several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own.[A18561,A18562,A18563,A18564,A174934] Marketed as the brand name product Tresiba, insulin degludec has a duration of action up to 42 hours allowing for once-daily dosing, typically at bedtime.[A18561,A18562,A18563,A18564,A174934] Due to its duration of action, Tresiba is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight.[A18561,A18562,A18563,A18564,A174934] Basal insulin is often combined with short-acting "bolus insulin" such as , , or to provide higher doses of insulin required following meals. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with the goal of avoiding any periods of hypoglycemia.[A18561,A18562,A18563,A18564,A174934] Compared to endogenous insulin, insulin degludec has an added hexadecanedioic acid on lysine at the B29 position, allowing for the formation of multi-hexamers.[A18561,A18562,A18563,A18564,A174934] When injected subcutaneously, these multi-hexamers form a drug depot store from which monomers are slowly and continuously absorbed into circulation.[A18561,A18562,A18563,A18564,A174934] As a result, Insulin Degludec has a protracted time action profile due to the delayed absorption from subcutaneous tissue depots into the systemic circulation.[A18561,A18562,A18563,A18564,A174934] Compared to available long-acting analogs such as and , which have a duration of action of 20-24 hours, insulin degludec provides a consistent level of basal insulin over 42 hours with a low peak: trough ratio.[A18561,A18562,A18563,A18564,A174934] Limitations of shorter-acting analogs include more frequent dosing and less stable pharmacokinetics, which may negatively impact patient adherence and glucose control, particularly nocturnal control.[A18561,A18562,A18563,A18564,A174934] Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst.[A18561,A18562,A18563,A18564,A174934] If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.[A18561,A18562,A18563,A18564,A174934] Insulin Degludec was approved by the FDA in September 2015 as the product Tresiba, for use in providing glycemic control to adults with diabetes mellitus.
Moderate
1
[ [ [ 318, 24, 1296 ] ], [ [ 318, 63, 1411 ], [ 1411, 24, 1296 ] ], [ [ 318, 24, 659 ], [ 659, 24, 1296 ] ], [ [ 318, 25, 1151 ], [ 1151, 24, 1296 ] ], [ [ 318, 64, 401 ], [ 401, 24, 1296 ] ], [ [ 318, 40, 1230 ], [ 1230, 24, 1296 ] ], [ [ 318, 62, 168 ], [ 168, 24, 1296 ] ], [ [ 318, 25, 877 ], [ 877, 63, 1296 ] ], [ [ 318, 63, 1411 ], [ 1411, 62, 1103 ], [ 1103, 23, 1296 ] ], [ [ 318, 24, 659 ], [ 659, 64, 17 ], [ 17, 24, 1296 ] ] ]
[ [ [ "Escitalopram", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin degludec" ] ], [ [ "Escitalopram", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tolbutamide" ], [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin degludec" ] ], [ [ "Escitalopram", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ], [ "Vilanterol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin degludec" ] ], [ [ "Escitalopram", "{u} may lead to a major life threatening interaction when taken with {v}", "Sunitinib" ], [ "Sunitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin degludec" ] ], [ [ "Escitalopram", "{u} may lead to a major life threatening interaction when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin degludec" ] ], [ [ "Escitalopram", "{u} (Compound) resembles {v} (Compound)", "Citalopram" ], [ "Citalopram", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin degludec" ] ], [ [ "Escitalopram", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin degludec" ] ], [ [ "Escitalopram", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ], [ "Macimorelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin degludec" ] ], [ [ "Escitalopram", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tolbutamide" ], [ "Tolbutamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Amcinonide" ], [ "Amcinonide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Insulin degludec" ] ], [ [ "Escitalopram", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ], [ "Vilanterol", "{u} may lead to a major life threatening interaction when taken with {v}", "Sotalol" ], [ "Sotalol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin degludec" ] ] ]
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec Escitalopram may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec Escitalopram may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec Escitalopram (Compound) resembles Citalopram (Compound) and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec Escitalopram may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec Escitalopram may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
DB01206
DB08908
37
713
[ "DDInter1086", "DDInter564" ]
Lomustine
Dimethyl fumarate
An alkylating agent of value against both hematologic malignancies and solid tumors.
Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera, and it was the third oral disease-modifying agent for multiple sclerosis approved by the FDA, following [fingolimod] and [teriflunomide]. Prior to its FDA approval, dimethyl fumarate had been used in Germany for treatment of psoriasis.
Moderate
1
[ [ [ 37, 24, 713 ] ], [ [ 37, 24, 996 ], [ 996, 24, 713 ] ], [ [ 37, 63, 60 ], [ 60, 24, 713 ] ], [ [ 37, 74, 552 ], [ 552, 24, 713 ] ], [ [ 37, 24, 270 ], [ 270, 63, 713 ] ], [ [ 37, 64, 770 ], [ 770, 24, 713 ] ], [ [ 37, 62, 147 ], [ 147, 24, 713 ] ], [ [ 37, 25, 976 ], [ 976, 25, 713 ] ], [ [ 37, 25, 779 ], [ 779, 64, 713 ] ], [ [ 37, 64, 1377 ], [ 1377, 25, 713 ] ] ]
[ [ [ "Lomustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dimethyl fumarate" ] ], [ [ "Lomustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bedaquiline" ], [ "Bedaquiline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dimethyl fumarate" ] ], [ [ "Lomustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Capecitabine" ], [ "Capecitabine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dimethyl fumarate" ] ], [ [ "Lomustine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carmustine" ], [ "Carmustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dimethyl fumarate" ] ], [ [ "Lomustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ocrelizumab" ], [ "Ocrelizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dimethyl fumarate" ] ], [ [ "Lomustine", "{u} may lead to a major life threatening interaction when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dimethyl fumarate" ] ], [ [ "Lomustine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vinblastine" ], [ "Vinblastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dimethyl fumarate" ] ], [ [ "Lomustine", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Dimethyl fumarate" ] ], [ [ "Lomustine", "{u} may lead to a major life threatening interaction when taken with {v}", "Smallpox (Vaccinia) Vaccine, Live" ], [ "Smallpox (Vaccinia) Vaccine, Live", "{u} may lead to a major life threatening interaction when taken with {v}", "Dimethyl fumarate" ] ], [ [ "Lomustine", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Dimethyl fumarate" ] ] ]
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate Lomustine (Compound) resembles Carmustine (Compound) and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate Lomustine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate Lomustine may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate Lomustine may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Dimethyl fumarate Lomustine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Dimethyl fumarate Lomustine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Dimethyl fumarate
DB00460
DB04571
612
226
[ "DDInter1929", "DDInter1877" ]
Verteporfin
Trioxsalen
Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.
Trioxsalen (trimethylpsoralen, trioxysalen or trisoralen) is a furanocoumarin and a psoralen derivative obtained from several plants, mainly Psoralea corylifolia. Like other psoralens it causes photosensitization of the skin. It is administered either topically or orally in conjunction with UV-A (the least damaging form of ultraviolet light) for phototherapy treatment of vitiligo and hand eczema. The photoactivated form produces interstrand linkages in DNA resulting in cell apoptosis. In research it can be conjugated to dyes for confocal microscopy and used to visualize sites of DNA damage.[3] The compound is has been explored for development of antisense oligonucleotides that can be cross-linked specifically to a mutant mRNA sequence without affecting normal transcripts differing at even a single base pair.
Moderate
1
[ [ [ 612, 24, 226 ] ], [ [ 612, 24, 92 ], [ 92, 24, 226 ] ], [ [ 612, 24, 1040 ], [ 1040, 7, 13128 ], [ 13128, 46, 226 ] ], [ [ 612, 24, 92 ], [ 92, 54, 19236 ], [ 19236, 15, 226 ] ], [ [ 612, 63, 1061 ], [ 1061, 7, 2699 ], [ 2699, 46, 226 ] ], [ [ 612, 24, 1195 ], [ 1195, 18, 10375 ], [ 10375, 57, 226 ] ], [ [ 612, 24, 1040 ], [ 1040, 63, 92 ], [ 92, 24, 226 ] ], [ [ 612, 24, 50 ], [ 50, 6, 2067 ], [ 2067, 46, 226 ] ], [ [ 612, 24, 1195 ], [ 1195, 24, 92 ], [ 92, 24, 226 ] ], [ [ 612, 63, 883 ], [ 883, 18, 10375 ], [ 10375, 57, 226 ] ] ]
[ [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trioxsalen" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methoxsalen" ], [ "Methoxsalen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trioxsalen" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dabrafenib" ], [ "Dabrafenib", "{u} (Compound) upregulates {v} (Gene)", "NARFL" ], [ "NARFL", "{u} (Gene) is upregulated by {v} (Compound)", "Trioxsalen" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methoxsalen" ], [ "Methoxsalen", "{u} (Compound) is included by {v} (Pharmacologic Class)", "Psoralens" ], [ "Psoralens", "{u} (Pharmacologic Class) includes {v} (Compound)", "Trioxsalen" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Treprostinil" ], [ "Treprostinil", "{u} (Compound) upregulates {v} (Gene)", "PLSCR1" ], [ "PLSCR1", "{u} (Gene) is upregulated by {v} (Compound)", "Trioxsalen" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Erlotinib" ], [ "Erlotinib", "{u} (Compound) downregulates {v} (Gene)", "RPS4Y1" ], [ "RPS4Y1", "{u} (Gene) is downregulated by {v} (Compound)", "Trioxsalen" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dabrafenib" ], [ "Dabrafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methoxsalen" ], [ "Methoxsalen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trioxsalen" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sulfasalazine" ], [ "Sulfasalazine", "{u} (Compound) binds {v} (Gene)", "IKBKB" ], [ "IKBKB", "{u} (Gene) is upregulated by {v} (Compound)", "Trioxsalen" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Erlotinib" ], [ "Erlotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methoxsalen" ], [ "Methoxsalen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trioxsalen" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gefitinib" ], [ "Gefitinib", "{u} (Compound) downregulates {v} (Gene)", "RPS4Y1" ], [ "RPS4Y1", "{u} (Gene) is downregulated by {v} (Compound)", "Trioxsalen" ] ] ]
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Trioxsalen Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib (Compound) upregulates NARFL (Gene) and NARFL (Gene) is upregulated by Trioxsalen (Compound) Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Methoxsalen (Compound) is included by Psoralens (Pharmacologic Class) and Psoralens (Pharmacologic Class) includes Trioxsalen (Compound) Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates PLSCR1 (Gene) and PLSCR1 (Gene) is upregulated by Trioxsalen (Compound) Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Trioxsalen (Compound) Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Trioxsalen Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) binds IKBKB (Gene) and IKBKB (Gene) is upregulated by Trioxsalen (Compound) Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Trioxsalen Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Trioxsalen (Compound)
DB00741
DB01122
167
158
[ "DDInter885", "DDInter61" ]
Hydrocortisone
Ambenonium
Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952.
Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis.
Moderate
1
[ [ [ 167, 24, 158 ] ], [ [ 167, 40, 870 ], [ 870, 24, 158 ] ], [ [ 167, 1, 251 ], [ 251, 24, 158 ] ], [ [ 167, 25, 1011 ], [ 1011, 63, 158 ] ], [ [ 167, 25, 770 ], [ 770, 24, 158 ] ], [ [ 167, 1, 1220 ], [ 1220, 63, 158 ] ], [ [ 167, 40, 870 ], [ 870, 1, 251 ], [ 251, 24, 158 ] ], [ [ 167, 1, 251 ], [ 251, 40, 870 ], [ 870, 24, 158 ] ], [ [ 167, 25, 1011 ], [ 1011, 64, 1042 ], [ 1042, 63, 158 ] ], [ [ 167, 25, 770 ], [ 770, 24, 1476 ], [ 1476, 63, 158 ] ] ]
[ [ [ "Hydrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ambenonium" ] ], [ [ "Hydrocortisone", "{u} (Compound) resembles {v} (Compound)", "Fludrocortisone" ], [ "Fludrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ambenonium" ] ], [ [ "Hydrocortisone", "{u} (Compound) resembles {v} (Compound)", "Betamethasone" ], [ "Betamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ambenonium" ] ], [ [ "Hydrocortisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Fingolimod" ], [ "Fingolimod", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ambenonium" ] ], [ [ "Hydrocortisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ambenonium" ] ], [ [ "Hydrocortisone", "{u} (Compound) resembles {v} (Compound)", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ambenonium" ] ], [ [ "Hydrocortisone", "{u} (Compound) resembles {v} (Compound)", "Fludrocortisone" ], [ "Fludrocortisone", "{u} (Compound) resembles {v} (Compound)", "Betamethasone" ], [ "Betamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ambenonium" ] ], [ [ "Hydrocortisone", "{u} (Compound) resembles {v} (Compound)", "Betamethasone" ], [ "Betamethasone", "{u} (Compound) resembles {v} (Compound)", "Fludrocortisone" ], [ "Fludrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ambenonium" ] ], [ [ "Hydrocortisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Fingolimod" ], [ "Fingolimod", "{u} may lead to a major life threatening interaction when taken with {v}", "Tetracosactide" ], [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ambenonium" ] ], [ [ "Hydrocortisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ], [ "Brigatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ambenonium" ] ] ]
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ambenonium Hydrocortisone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ambenonium Hydrocortisone may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Ambenonium Hydrocortisone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ambenonium Hydrocortisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ambenonium Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ambenonium Hydrocortisone (Compound) resembles Betamethasone (Compound) and Betamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ambenonium Hydrocortisone may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Ambenonium Hydrocortisone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ambenonium
DB00086
DB00682
1,167
126
[ "DDInter1712", "DDInter1951" ]
Streptokinase
Warfarin
Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Major
2
[ [ [ 1167, 25, 126 ] ], [ [ 1167, 23, 944 ], [ 944, 62, 126 ] ], [ [ 1167, 24, 477 ], [ 477, 62, 126 ] ], [ [ 1167, 24, 557 ], [ 557, 63, 126 ] ], [ [ 1167, 24, 1100 ], [ 1100, 24, 126 ] ], [ [ 1167, 63, 1595 ], [ 1595, 24, 126 ] ], [ [ 1167, 24, 1171 ], [ 1171, 64, 126 ] ], [ [ 1167, 25, 405 ], [ 405, 64, 126 ] ], [ [ 1167, 64, 942 ], [ 942, 25, 126 ] ], [ [ 1167, 25, 553 ], [ 553, 25, 126 ] ] ]
[ [ [ "Streptokinase", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ] ], [ [ "Streptokinase", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Chamomile" ], [ "Chamomile", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Warfarin" ] ], [ [ "Streptokinase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cilostazol" ], [ "Cilostazol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Warfarin" ] ], [ [ "Streptokinase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deoxycholic acid" ], [ "Deoxycholic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ] ], [ [ "Streptokinase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Venlafaxine" ], [ "Venlafaxine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ] ], [ [ "Streptokinase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Collagenase clostridium histolyticum" ], [ "Collagenase clostridium histolyticum", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ] ], [ [ "Streptokinase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Meloxicam" ], [ "Meloxicam", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ] ], [ [ "Streptokinase", "{u} may lead to a major life threatening interaction when taken with {v}", "Acalabrutinib" ], [ "Acalabrutinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ] ], [ [ "Streptokinase", "{u} may lead to a major life threatening interaction when taken with {v}", "Bivalirudin" ], [ "Bivalirudin", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ] ], [ [ "Streptokinase", "{u} may lead to a major life threatening interaction when taken with {v}", "Fondaparinux" ], [ "Fondaparinux", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ] ] ]
Streptokinase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Warfarin Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Warfarin Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Warfarin Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Warfarin Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam may lead to a major life threatening interaction when taken with Warfarin Streptokinase may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Warfarin Streptokinase may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may lead to a major life threatening interaction when taken with Warfarin Streptokinase may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Warfarin
DB00502
DB01181
1,300
1,532
[ "DDInter853", "DDInter906" ]
Haloperidol
Ifosfamide
Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and mesocortical systems of the brain. Haloperidol is indicated for the treatment of the manifestations of several psychotic disorders including schizophrenia, acute psychosis, Tourette syndrome, and other severe behavioural states. It is also used off-label for the management of chorea associated with Huntington's disease and for the treatment of intractable hiccups as it is a potent antiemetic. Dopamine-antagonizing medications such as haloperidol are though to improve psychotic symptoms and states that are caused by an over-production of dopamine, such as schizophrenia, which is
Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Moderate
1
[ [ [ 1300, 24, 1532 ] ], [ [ 1300, 6, 7524 ], [ 7524, 45, 1532 ] ], [ [ 1300, 21, 29209 ], [ 29209, 60, 1532 ] ], [ [ 1300, 63, 1648 ], [ 1648, 24, 1532 ] ], [ [ 1300, 25, 351 ], [ 351, 63, 1532 ] ], [ [ 1300, 25, 401 ], [ 401, 24, 1532 ] ], [ [ 1300, 24, 723 ], [ 723, 24, 1532 ] ], [ [ 1300, 24, 849 ], [ 849, 63, 1532 ] ], [ [ 1300, 64, 475 ], [ 475, 24, 1532 ] ], [ [ 1300, 23, 663 ], [ 663, 24, 1532 ] ] ]
[ [ [ "Haloperidol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ifosfamide" ] ], [ [ "Haloperidol", "{u} (Compound) binds {v} (Gene)", "CYP3A5" ], [ "CYP3A5", "{u} (Gene) is bound by {v} (Compound)", "Ifosfamide" ] ], [ [ "Haloperidol", "{u} (Compound) causes {v} (Side Effect)", "Anorexia" ], [ "Anorexia", "{u} (Side Effect) is caused by {v} (Compound)", "Ifosfamide" ] ], [ [ "Haloperidol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aldesleukin" ], [ "Aldesleukin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ifosfamide" ] ], [ [ "Haloperidol", "{u} may lead to a major life threatening interaction when taken with {v}", "Ribociclib" ], [ "Ribociclib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ifosfamide" ] ], [ [ "Haloperidol", "{u} may lead to a major life threatening interaction when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ifosfamide" ] ], [ [ "Haloperidol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aprepitant" ], [ "Aprepitant", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ifosfamide" ] ], [ [ "Haloperidol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ifosfamide" ] ], [ [ "Haloperidol", "{u} may lead to a major life threatening interaction when taken with {v}", "Morphine" ], [ "Morphine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ifosfamide" ] ], [ [ "Haloperidol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ifosfamide" ] ] ]
Haloperidol (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Ifosfamide (Compound) Haloperidol (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Ifosfamide (Compound) Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide Haloperidol may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide Haloperidol may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide Haloperidol may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide Haloperidol may cause a minor interaction that can limit clinical effects when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
DB00757
DB14568
1,166
982
[ "DDInter581", "DDInter1000" ]
Dolasetron
Ivosidenib
Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023.
Major
2
[ [ [ 1166, 25, 982 ] ], [ [ 1166, 23, 112 ], [ 112, 23, 982 ] ], [ [ 1166, 64, 1081 ], [ 1081, 24, 982 ] ], [ [ 1166, 24, 543 ], [ 543, 24, 982 ] ], [ [ 1166, 63, 867 ], [ 867, 24, 982 ] ], [ [ 1166, 25, 1322 ], [ 1322, 24, 982 ] ], [ [ 1166, 24, 159 ], [ 159, 63, 982 ] ], [ [ 1166, 64, 472 ], [ 472, 25, 982 ] ], [ [ 1166, 25, 1301 ], [ 1301, 25, 982 ] ], [ [ 1166, 63, 828 ], [ 828, 25, 982 ] ] ]
[ [ [ "Dolasetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ] ], [ [ "Dolasetron", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ivosidenib" ] ], [ [ "Dolasetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Nicardipine" ], [ "Nicardipine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Dolasetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Loperamide" ], [ "Loperamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Dolasetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olanzapine" ], [ "Olanzapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Dolasetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Alfentanil" ], [ "Alfentanil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Dolasetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ], [ "Larotrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ] ], [ [ "Dolasetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Alfuzosin" ], [ "Alfuzosin", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ] ], [ [ "Dolasetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Levacetylmethadol" ], [ "Levacetylmethadol", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ] ], [ [ "Dolasetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Oxycodone" ], [ "Oxycodone", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ] ] ]
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib Dolasetron may lead to a major life threatening interaction when taken with Nicardipine and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Dolasetron may lead to a major life threatening interaction when taken with Alfentanil and Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib Dolasetron may lead to a major life threatening interaction when taken with Alfuzosin and Alfuzosin may lead to a major life threatening interaction when taken with Ivosidenib Dolasetron may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol may lead to a major life threatening interaction when taken with Ivosidenib Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone may lead to a major life threatening interaction when taken with Ivosidenib
DB01124
DB14730
1,411
1,412
[ "DDInter1828", "DDInter264" ]
Tolbutamide
Calaspargase pegol
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating Ξ² cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic Ξ² cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to
Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparaginase treatment in ALL , , . Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL . The asparagine specific enzyme is derived from Escherichia coli, as a conjugate of L-asparaginase (L-asparagine amidohydrolase) and monomethoxypolyethylene glycol (mPEG) with a succinimidyl carbonate (SC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA label], . Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) .
Moderate
1
[ [ [ 1411, 24, 1412 ] ], [ [ 1411, 62, 1347 ], [ 1347, 24, 1412 ] ], [ [ 1411, 24, 5 ], [ 5, 24, 1412 ] ], [ [ 1411, 63, 1144 ], [ 1144, 24, 1412 ] ], [ [ 1411, 1, 959 ], [ 959, 24, 1412 ] ], [ [ 1411, 64, 600 ], [ 600, 24, 1412 ] ], [ [ 1411, 63, 1101 ], [ 1101, 25, 1412 ] ], [ [ 1411, 62, 1347 ], [ 1347, 25, 792 ], [ 792, 24, 1412 ] ], [ [ 1411, 24, 5 ], [ 5, 63, 1144 ], [ 1144, 24, 1412 ] ], [ [ 1411, 63, 1144 ], [ 1144, 24, 159 ], [ 159, 24, 1412 ] ] ]
[ [ [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calaspargase pegol" ] ], [ [ "Tolbutamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Clopidogrel" ], [ "Clopidogrel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calaspargase pegol" ] ], [ [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liraglutide" ], [ "Liraglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calaspargase pegol" ] ], [ [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ], [ "Nateglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calaspargase pegol" ] ], [ [ "Tolbutamide", "{u} (Compound) resembles {v} (Compound)", "Glipizide" ], [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calaspargase pegol" ] ], [ [ "Tolbutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calaspargase pegol" ] ], [ [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may lead to a major life threatening interaction when taken with {v}", "Calaspargase pegol" ] ], [ [ "Tolbutamide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Clopidogrel" ], [ "Clopidogrel", "{u} may lead to a major life threatening interaction when taken with {v}", "Rivaroxaban" ], [ "Rivaroxaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calaspargase pegol" ] ], [ [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liraglutide" ], [ "Liraglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ], [ "Nateglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calaspargase pegol" ] ], [ [ "Tolbutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nateglinide" ], [ "Nateglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ], [ "Larotrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calaspargase pegol" ] ] ]
Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol Tolbutamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol Tolbutamide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Calaspargase pegol Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
DB00063
DB04865
366
4
[ "DDInter659", "DDInter1335" ]
Eptifibatide
Omacetaxine mepesuccinate
Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
Major
2
[ [ [ 366, 25, 4 ] ], [ [ 366, 24, 738 ], [ 738, 63, 4 ] ], [ [ 366, 25, 39 ], [ 39, 63, 4 ] ], [ [ 366, 25, 1213 ], [ 1213, 24, 4 ] ], [ [ 366, 24, 831 ], [ 831, 25, 4 ] ], [ [ 366, 25, 1650 ], [ 1650, 64, 4 ] ], [ [ 366, 25, 1317 ], [ 1317, 25, 4 ] ], [ [ 366, 64, 1432 ], [ 1432, 25, 4 ] ], [ [ 366, 63, 942 ], [ 942, 25, 4 ] ], [ [ 366, 24, 578 ], [ 578, 64, 4 ] ] ]
[ [ [ "Eptifibatide", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Eptifibatide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Niraparib" ], [ "Niraparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Eptifibatide", "{u} may lead to a major life threatening interaction when taken with {v}", "Panobinostat" ], [ "Panobinostat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Eptifibatide", "{u} may lead to a major life threatening interaction when taken with {v}", "Dasatinib" ], [ "Dasatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Eptifibatide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Indomethacin" ], [ "Indomethacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Eptifibatide", "{u} may lead to a major life threatening interaction when taken with {v}", "Avapritinib" ], [ "Avapritinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Eptifibatide", "{u} may lead to a major life threatening interaction when taken with {v}", "Dipyridamole" ], [ "Dipyridamole", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Eptifibatide", "{u} may lead to a major life threatening interaction when taken with {v}", "Abciximab" ], [ "Abciximab", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Eptifibatide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bivalirudin" ], [ "Bivalirudin", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Eptifibatide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ] ] ]
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate Eptifibatide may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate Eptifibatide may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate Eptifibatide may lead to a major life threatening interaction when taken with Avapritinib and Avapritinib may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate Eptifibatide may lead to a major life threatening interaction when taken with Dipyridamole and Dipyridamole may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate Eptifibatide may lead to a major life threatening interaction when taken with Abciximab and Abciximab may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Bivalirudin and Bivalirudin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
DB00586
DB01276
1,512
123
[ "DDInter537", "DDInter706" ]
Diclofenac
Exenatide
Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes. Diclofenac was the product of rational drug design based on the structures of [phenylbutazone], [mefenamic acid], and [indomethacin]. The addition of two chlorine groups in the ortho position of the phenyl ring locks the ring in maximal torsion which appears to be related to increased potency. It is often used in combination with [misoprostol] to prevent NSAID-induced gastric ulcers. Diclofenac was first approved by the
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
Moderate
1
[ [ [ 1512, 24, 123 ] ], [ [ 1512, 63, 1252 ], [ 1252, 23, 123 ] ], [ [ 1512, 24, 1573 ], [ 1573, 24, 123 ] ], [ [ 1512, 63, 217 ], [ 217, 24, 123 ] ], [ [ 1512, 35, 1338 ], [ 1338, 24, 123 ] ], [ [ 1512, 24, 1040 ], [ 1040, 63, 123 ] ], [ [ 1512, 25, 126 ], [ 126, 24, 123 ] ], [ [ 1512, 25, 4 ], [ 4, 63, 123 ] ], [ [ 1512, 64, 886 ], [ 886, 24, 123 ] ], [ [ 1512, 62, 417 ], [ 417, 24, 123 ] ] ]
[ [ [ "Diclofenac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Diclofenac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Digoxin" ], [ "Digoxin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Exenatide" ] ], [ [ "Diclofenac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisone" ], [ "Prednisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Diclofenac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olmesartan" ], [ "Olmesartan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Diclofenac", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Meclofenamic acid" ], [ "Meclofenamic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Diclofenac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dabrafenib" ], [ "Dabrafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Diclofenac", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Diclofenac", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ], [ "Omacetaxine mepesuccinate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Diclofenac", "{u} may lead to a major life threatening interaction when taken with {v}", "Ketorolac" ], [ "Ketorolac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ], [ [ "Diclofenac", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sucralfate" ], [ "Sucralfate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ] ] ]
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Diclofenac (Compound) resembles Meclofenamic acid (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Diclofenac may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Diclofenac may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Diclofenac may lead to a major life threatening interaction when taken with Ketorolac and Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Exenatide Diclofenac may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
DB01056
DB04865
571
4
[ "DDInter1823", "DDInter1335" ]
Tocainide
Omacetaxine mepesuccinate
An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels.
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
Moderate
1
[ [ [ 571, 24, 4 ] ], [ [ 571, 18, 8397 ], [ 8397, 46, 4 ] ], [ [ 571, 24, 1683 ], [ 1683, 63, 4 ] ], [ [ 571, 63, 599 ], [ 599, 24, 4 ] ], [ [ 571, 25, 1292 ], [ 1292, 64, 4 ] ], [ [ 571, 24, 976 ], [ 976, 64, 4 ] ], [ [ 571, 64, 1064 ], [ 1064, 25, 4 ] ], [ [ 571, 18, 8397 ], [ 8397, 56, 13042 ], [ 13042, 46, 4 ] ], [ [ 571, 18, 8800 ], [ 8800, 17, 14560 ], [ 14560, 46, 4 ] ], [ [ 571, 24, 1683 ], [ 1683, 63, 1394 ], [ 1394, 24, 4 ] ] ]
[ [ [ "Tocainide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Tocainide", "{u} (Compound) downregulates {v} (Gene)", "PPP2R3C" ], [ "PPP2R3C", "{u} (Gene) is upregulated by {v} (Compound)", "Omacetaxine mepesuccinate" ] ], [ [ "Tocainide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ], [ "Ustekinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Tocainide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alemtuzumab" ], [ "Alemtuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Tocainide", "{u} may lead to a major life threatening interaction when taken with {v}", "Deferiprone" ], [ "Deferiprone", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Tocainide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Tocainide", "{u} may lead to a major life threatening interaction when taken with {v}", "Cladribine" ], [ "Cladribine", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Tocainide", "{u} (Compound) downregulates {v} (Gene)", "PPP2R3C" ], [ "PPP2R3C", "{u} (Gene) is regulated by {v} (Gene)", "HIST1H2BK" ], [ "HIST1H2BK", "{u} (Gene) is upregulated by {v} (Compound)", "Omacetaxine mepesuccinate" ] ], [ [ "Tocainide", "{u} (Compound) downregulates {v} (Gene)", "RBM34" ], [ "RBM34", "{u} (Gene) regulates {v} (Gene)", "STAP2" ], [ "STAP2", "{u} (Gene) is upregulated by {v} (Compound)", "Omacetaxine mepesuccinate" ] ], [ [ "Tocainide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ], [ "Ustekinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rituximab" ], [ "Rituximab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ] ]
Tocainide (Compound) downregulates PPP2R3C (Gene) and PPP2R3C (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) Tocainide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate Tocainide may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate Tocainide may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate Tocainide may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate Tocainide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate Tocainide (Compound) downregulates PPP2R3C (Gene) and PPP2R3C (Gene) is regulated by HIST1H2BK (Gene) and HIST1H2BK (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) Tocainide (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) regulates STAP2 (Gene) and STAP2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) Tocainide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Rituximab and Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
DB06176
DB09054
1,342
384
[ "DDInter1616", "DDInter905" ]
Romidepsin
Idelalisib
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110Ξ΄, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110Ξ± and p110Ξ², p110Ξ΄ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
Moderate
1
[ [ [ 1342, 24, 384 ] ], [ [ 1342, 64, 318 ], [ 318, 23, 384 ] ], [ [ 1342, 63, 479 ], [ 479, 23, 384 ] ], [ [ 1342, 25, 1618 ], [ 1618, 24, 384 ] ], [ [ 1342, 24, 241 ], [ 241, 63, 384 ] ], [ [ 1342, 63, 58 ], [ 58, 24, 384 ] ], [ [ 1342, 24, 1468 ], [ 1468, 24, 384 ] ], [ [ 1342, 64, 228 ], [ 228, 24, 384 ] ], [ [ 1342, 62, 1247 ], [ 1247, 24, 384 ] ], [ [ 1342, 25, 1259 ], [ 1259, 64, 384 ] ] ]
[ [ [ "Romidepsin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ] ], [ [ "Romidepsin", "{u} may lead to a major life threatening interaction when taken with {v}", "Escitalopram" ], [ "Escitalopram", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Idelalisib" ] ], [ [ "Romidepsin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Donepezil" ], [ "Donepezil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Idelalisib" ] ], [ [ "Romidepsin", "{u} may lead to a major life threatening interaction when taken with {v}", "Cabozantinib" ], [ "Cabozantinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ] ], [ [ "Romidepsin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Erdafitinib" ], [ "Erdafitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ] ], [ [ "Romidepsin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alefacept" ], [ "Alefacept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ] ], [ [ "Romidepsin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ponatinib" ], [ "Ponatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ] ], [ [ "Romidepsin", "{u} may lead to a major life threatening interaction when taken with {v}", "Dofetilide" ], [ "Dofetilide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ] ], [ [ "Romidepsin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sulfamethoxazole" ], [ "Sulfamethoxazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ] ], [ [ "Romidepsin", "{u} may lead to a major life threatening interaction when taken with {v}", "Baricitinib" ], [ "Baricitinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Idelalisib" ] ] ]
Romidepsin may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Idelalisib Romidepsin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and Erdafitinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib Romidepsin may lead to a major life threatening interaction when taken with Dofetilide and Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib Romidepsin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib Romidepsin may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Idelalisib
DB00196
DB01267
600
519
[ "DDInter743", "DDInter1381" ]
Fluconazole
Paliperidone
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]
Moderate
1
[ [ [ 600, 24, 519 ] ], [ [ 600, 24, 1664 ], [ 1664, 1, 519 ] ], [ [ 600, 25, 924 ], [ 924, 1, 519 ] ], [ [ 600, 6, 7524 ], [ 7524, 45, 519 ] ], [ [ 600, 21, 28898 ], [ 28898, 60, 519 ] ], [ [ 600, 23, 112 ], [ 112, 23, 519 ] ], [ [ 600, 24, 36 ], [ 36, 63, 519 ] ], [ [ 600, 25, 959 ], [ 959, 24, 519 ] ], [ [ 600, 24, 473 ], [ 473, 24, 519 ] ], [ [ 600, 63, 521 ], [ 521, 24, 519 ] ] ]
[ [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paliperidone" ] ], [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Risperidone" ], [ "Risperidone", "{u} (Compound) resembles {v} (Compound)", "Paliperidone" ] ], [ [ "Fluconazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Iloperidone" ], [ "Iloperidone", "{u} (Compound) resembles {v} (Compound)", "Paliperidone" ] ], [ [ "Fluconazole", "{u} (Compound) binds {v} (Gene)", "CYP3A5" ], [ "CYP3A5", "{u} (Gene) is bound by {v} (Compound)", "Paliperidone" ] ], [ [ "Fluconazole", "{u} (Compound) causes {v} (Side Effect)", "Constipation" ], [ "Constipation", "{u} (Side Effect) is caused by {v} (Compound)", "Paliperidone" ] ], [ [ "Fluconazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Paliperidone" ] ], [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Eribulin" ], [ "Eribulin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paliperidone" ] ], [ [ "Fluconazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paliperidone" ] ], [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Repaglinide" ], [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paliperidone" ] ], [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Goserelin" ], [ "Goserelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paliperidone" ] ] ]
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound) Fluconazole may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Compound) Fluconazole (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paliperidone (Compound) Fluconazole (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Paliperidone (Compound) Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Paliperidone Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone Fluconazole may lead to a major life threatening interaction when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone
DB11689
DB12130
321
1,017
[ "DDInter1659", "DDInter1094" ]
Selumetinib
Lorlatinib
Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming. However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumours in Phase II trials. Currently, the novel MEK 1 / 2 inhibitor, selumetinib, is approved solely for the treatment of Neurofibromatosis type 1 (NF-1) in a limited age group. NF-1 is considered rare, with an estimated incidence of 1/3000 individuals. It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications, including the development of
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Major
2
[ [ [ 321, 25, 1017 ] ], [ [ 321, 63, 1101 ], [ 1101, 23, 1017 ] ], [ [ 321, 24, 1421 ], [ 1421, 63, 1017 ] ], [ [ 321, 63, 126 ], [ 126, 24, 1017 ] ], [ [ 321, 24, 1320 ], [ 1320, 24, 1017 ] ], [ [ 321, 64, 1419 ], [ 1419, 24, 1017 ] ], [ [ 321, 25, 351 ], [ 351, 24, 1017 ] ], [ [ 321, 64, 1220 ], [ 1220, 25, 1017 ] ], [ [ 321, 25, 283 ], [ 283, 64, 1017 ] ], [ [ 321, 25, 913 ], [ 913, 25, 1017 ] ] ]
[ [ [ "Selumetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Lorlatinib" ] ], [ [ "Selumetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Lorlatinib" ] ], [ [ "Selumetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Betrixaban" ], [ "Betrixaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Selumetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Selumetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elagolix" ], [ "Elagolix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Selumetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Imatinib" ], [ "Imatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Selumetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Ribociclib" ], [ "Ribociclib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Selumetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may lead to a major life threatening interaction when taken with {v}", "Lorlatinib" ] ], [ [ "Selumetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Fedratinib" ], [ "Fedratinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Lorlatinib" ] ], [ [ "Selumetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Apalutamide" ], [ "Apalutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Lorlatinib" ] ] ]
Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Selumetinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Selumetinib may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Selumetinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Selumetinib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Lorlatinib Selumetinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Lorlatinib Selumetinib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Lorlatinib
DB01105
DB14509
222
1,399
[ "DDInter1665", "DDInter1081" ]
Sibutramine
Lithium carbonate
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.
Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].
Major
2
[ [ [ 222, 25, 1399 ] ], [ [ 222, 63, 874 ], [ 874, 23, 1399 ] ], [ [ 222, 24, 1574 ], [ 1574, 23, 1399 ] ], [ [ 222, 24, 1385 ], [ 1385, 24, 1399 ] ], [ [ 222, 64, 506 ], [ 506, 24, 1399 ] ], [ [ 222, 63, 1674 ], [ 1674, 24, 1399 ] ], [ [ 222, 23, 609 ], [ 609, 24, 1399 ] ], [ [ 222, 25, 1264 ], [ 1264, 24, 1399 ] ], [ [ 222, 62, 600 ], [ 600, 24, 1399 ] ], [ [ 222, 23, 351 ], [ 351, 25, 1399 ] ] ]
[ [ [ "Sibutramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Lithium carbonate" ] ], [ [ "Sibutramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Epinephrine" ], [ "Epinephrine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Lithium carbonate" ] ], [ [ "Sibutramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Urea" ], [ "Urea", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Lithium carbonate" ] ], [ [ "Sibutramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ], [ "Semaglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lithium carbonate" ] ], [ [ "Sibutramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Dextromethorphan" ], [ "Dextromethorphan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lithium carbonate" ] ], [ [ "Sibutramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ], [ "Orciprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lithium carbonate" ] ], [ [ "Sibutramine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lithium carbonate" ] ], [ [ "Sibutramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lithium carbonate" ] ], [ [ "Sibutramine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lithium carbonate" ] ], [ [ "Sibutramine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ribociclib" ], [ "Ribociclib", "{u} may lead to a major life threatening interaction when taken with {v}", "Lithium carbonate" ] ] ]
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Urea and Urea may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate Sibutramine may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate Sibutramine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate Sibutramine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate Sibutramine may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Lithium carbonate
End of preview. Expand in Data Studio

πŸ”— This dataset is part of the study:

K-Paths: Reasoning over Graph Paths for Drug Repurposing and Drug Interaction Prediction

DDInter: Inductive Reasoning Dataset

DDInter provides drug–drug interaction (DDI) data labeled with three severity levels (Major, Moderate, Minor). Each entry includes two drugs, an interaction label, drug descriptions, and structured/natural language representations of multi-hop reasoning paths between them. The multi-hop paths were extracted from a biomedical knowledge graph (Hetionet) using K-Paths.

This dataset is useful for evaluating:

  • Path-based biomedical reasoning
  • Knowledge graph inference
  • Inductive reasoning

πŸ’‘ Columns

Column Description
drug1_db, drug2_db DrugBank IDs
drug1_id, drug2_id Node IDs from the KG
drug_pair Optional drug pair identifier
drug1_name, drug2_name Names of each drug
drug1_desc, drug2_desc Descriptions of each drug
label Interaction severity (e.g., Moderate)
label_idx Numeric version of the label
all_paths, all_paths_str, path_str KG paths for reasoning

πŸ“¦ Example Record

{
  "drug1_name": "Mannitol",
  "drug2_name": "Castor oil",
  "label": "Moderate",
  "path_str": "Mannitol (Compound) binds ABCB1 (Gene) and ABCG2 (Gene)..."
}

## πŸ“₯ How to Load with pandas

```python
import pandas as pd

splits = {
    "train": "ddinter/train.json",
    "test": "ddinter/test.json"
}

train = pd.read_json("hf://datasets/Tassy24/K-Paths-inductive-reasoning-ddinter/" + splits["train"], lines=True)
test = pd.read_json("hf://datasets/Tassy24/K-Paths-inductive-reasoning-ddinter/" + splits["test"], lines=True)



### πŸ“œ Citation (BibTeX)

```bibtex
@article{abdullahi2025k,
  title={K-Paths: Reasoning over Graph Paths for Drug Repurposing and Drug Interaction Prediction},
  author={Abdullahi, Tassallah and Gemou, Ioanna and Nayak, Nihal V and Murtaza, Ghulam and Bach, Stephen H and Eickhoff, Carsten and Singh, Ritambhara},
  journal={arXiv preprint arXiv:2502.13344},
  year={2025}
}
Downloads last month
72